Drug Approvals International – Page 134 – All about Drugs Live by Dr Anthony Melvin Crasto

TROXACITABINE троксацитабин , تروكساسيتابين , 曲沙他滨 ,

Troxacitabine CAS 145918-75-8 Molecular FormulaC8H11N3O4 Average mass213.191 Da троксацитабин تروكساسيتابين 曲沙他滨 2(1H)-Pyrimidinone, 4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]- Hmd-cytosine; NCGC00183848-01; Beta-L-Dioxolane-cytidine; 4-amino-1-[(2S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one; 2R(-)-cis-Hmd-cytosine, (-)-ODDC 4-amino-1-[(2S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.[1] Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being …

Astellas Pharma Inc. new Glucokinase Activator, ASP ? for Type 2 Diabetes

ASP ? (2R)-2-(4-cyclopropanesulfonyl-3-cyclopropylphenyl)-N-[5-(hydroxymethyl)pyrazin-2-yl]-3-[(R)-3-oxocyclopentyl]propanamide CAS 1174229-89-0 MW C25 H29 N3 O5 S Benzeneacetamide, 3-cyclopropyl-4-(cyclopropylsulfonyl)-N-[5-(hydroxymethyl)-2-pyrazinyl]-α-[[(1R)-3-oxocyclopentyl]methyl]-, (αR)- Molecular Weight, 483.58 [α]D20 −128.7 (c 1.00, MeOH); 1H NMR (DMSO-d6, 400 MHz) δ 11.07 (s, 1H), 9.20 (d, J = 1.4 Hz, 1H), 8.41 (d, J = 1.4 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.41 (dd, J …

FDA approves first treatment Noctiva (Desmopressin acetate) nasal spray for frequent urination at night due to overproduction of urine

Desmopressin acetate FDA approves first treatment for frequent urination at night due to overproduction of urine 03/03/2017 The U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the …

Oxymetazoline, оксиметазолин , أوكسيميتازولين , 羟甲唑啉

Oxymetazoline 1491-59-4 CAS NUMBER Molecular FormulaC16H24N2O Average mass260.375 Da Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- оксиметазолин أوكسيميتازولين 羟甲唑啉 Oxymetazoline is a selective α1 adrenergic receptor agonist and α2 adrenergic receptor partial agonist. It is a topical decongestant, used in the form of oxymetazoline hydrochloride. It was developed from xylometazoline at E. Merck Darmstadt by Fruhstorfer in 1961.[1] Oxymetazoline is …

Ramizol

1,3,5-Tris[(1E)-2′-(4′′-benzoic acid)vinyl]benzene] (Ramizol™) TSB-007 CAS 1292817-44-7 MF C33 H24 O6 MW 516.54 Benzoic acid, 4,4′,4”-[1,3,5-benzenetriyltri-(1E)-2,1-ethenediyl]tris- 4,4′,4”-[1,3,5-Benzenetriyltri-(1E)-2,1-ethenediyl]tris[benzoic acid] University of Western Australia (UWA) (Originator) Allan James Mckinley, Thomas V Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos Applicant The University Of Western Australia 1,3,5-Tris[(1E)-2′-(4′′-benzoic acid)vinyl]benzene] (Ramizol™) is a potent and non-toxic synthetic antimicrobial agent, and we now …

FDA approves Odactra for house dust mite allergies

FDA approves Odactra for house dust mite allergies 03/01/2017 The U.S. Food and Drug Administration today approved Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), in people 18 through 65 years of age. March 1, …

FDA approves Xermelo (telotristat ethyl) for carcinoid syndrome diarrhea

Telotristat ethyl Molecular Formula, C27-H26-Cl-F3-N6-O3, Molecular Weight, 574.9884, RN: 1033805-22-9 UNII: 8G388563M LX 1032 (2S)-2-Amino-3-[4-[2-amino-6-[[(1R)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethyl]oxy]pyrimidin-4-yl]phenyl]propionic acid ethyl ester Ethyl-4-(2-amino-6-{(1R)-1-[4-chlor-2-(3-methyl-1H-pyrazol-1-yl)phenyl]-2,2,2-trifluorethoxy}-4-pyrimidinyl)-L-phenylalaninat L-Phenylalanine, 4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]-4-pyrimidinyl]-, ethyl ester SEE…………… Telotristat etiprate, (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate 2-benzamidoacetate . CAS: 1137608-69-5 (etiprate), LX 1606 Chemical Formula: C36H35ClF3N7O6 Molecular Weight: 754.16 L-Phenylalanine, 4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]-4-pyrimidinyl]-, ethyl ester, compd. with N-benzoylglycine (1:1) LX 1032 hippurate LX 1606 SEE ALSO…………. …

Tradipitant, традипитант , تراديبيتانت , 曲地匹坦 ,

Tradipitant VLY-686, LY686017 традипитант تراديبيتانت [Arabic] 曲地匹坦 [Chinese] Molecular Formula C28H16ClF6N5O Average mass 587.903 Da 622370-35-8 CAS Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (2-(1-(3,5-bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)methanone PHASE 2, Gastroparesis; Pruritus Tradipitant, PHASE 2, VLY-686, LY686017, традипитант , تراديبيتانت , 曲地匹坦 , VANDA, ELI LILLY, Gastroparesis Pruritus, FDA 2025, APPROVALS 2025, vomiting associated with motion pyridine-containing NK-1 receptor antagonist ie tradipitant, useful for treating anxiety, pruritus and alcoholism. Vanda Pharmaceuticals, under license …

Zydus Cadila to launch India’s 1st Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4

Zydus Cadila to launch India’s 1st Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4 Ahmedabad, February 24, 2017 Zydus Cadila, a research-driven, global healthcare provider has received approvals from the Drug Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO) and the Central Drug Laboratory (CDL) to market the Tetravalent Inactivated Influenza vaccine …

Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC)

Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC) Read more: https://goo.gl/eugRnZ #ZydusAnnouncement Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC) Ahmedabad, India, February 23, 2017 Zydus Cadila, a research-driven, …